SOMERSET, N.J., Jan. 16, 2012 /PRNewswire/ -- Terumo
Americas Holding, Inc. (TAH), a U.S. subsidiary of Japan's Terumo Corporation, one of the world's
leading medical device manufacturers with $4
billion in sales and operations in more than 160 nations,
today announced that it has acquired Onset Medical Corporation
("Onset"), an innovative medical device company located in
Irvine, CA, that focuses on
developing first-in-class access sheath technology designed for
multiple, minimally invasive clinical applications in cardiology
and urology.
Using its proprietary Controlled Deployment Technology (CDT)
platform, Onset has developed the smallest sheath profiles with the
largest internal diameters of any available access sheath to
protect against unnecessary access site or arterial trauma for the
patient. Onset's Associates will join with TAH subsidiary Terumo
Medical Corporation as part of its Terumo Interventional Systems
(TIS) business unit, where the CDT platform will complement TIS'
complete product line of industry leading entry site management and
lesion access technologies.
Terumo customers will have access to Onset's complete product
lines. The SoloPath™ Balloon Expandable Transfemoral and
Transseptal Catheters' expandable and collapsable sheath technology
allows TIS to enter the global structural heart and aneurysmal
repair markets, providing an access platform for complex,
large-bore procedures including Transcatheter Aortic Valve
Implantation (TAVI), Thoracic Endovascular Aortic/Aneurysm Repair
(TVAR) and Endovascular Aneurysm/Aortic Repair (EVAR). The
Pathway™ Balloon Expandable PCNL Sheath and Pathway™ Balloon
Expandable Ureteral Access Sheath provide physicians with a
one-step option for performing procedures such as Percutaneous
Nephrolithotomy in the removal of large renal calculi (kidney
stones).
"We welcome Onset to the Terumo family and look forward to
providing our customers with current and future products based on
the exciting CDT platform, which represents a tremendous complement
to our overall value proposition as the leaders in entry site
management and lesion access," said James
Rushworth, Senior Vice President and General Manager, Terumo
Medical Corporation and President, Onset Medical Corporation.
"CDT literally changes the way physicians enter the vascular system
and manage the access site, while allowing them to achieve easier,
safer access to the target lesion in a variety of clinical
applications. This strategic acquisition reinforces our
commitment to pursuing unique technologies that meet the
specialized needs of our customers and contribute to better
outcomes for their patients."
As a global leader in vascular access management, TIS can
effectively maximize the potential of the CDT-based platform when
compared with competitors who do not specialize in entry site
management.
"When Terumo approached us, it quickly became clear that they
were the established leader in entry site management and the best
company to commercialize our sheath technology on a global scale,"
said Joseph Bishop, Vice President
and Chief Operating Officer, Onset Medical Corporation. "It is
gratifying to know that our unique devices will immediately
strengthen their core capability and will be featured prominently
among other class-leading technologies that drive better patient
outcomes."
For more information, contact Robert
Murphy, The Storch-Murphy Group,
908.276.0777.
Terumo Interventional Systems
Terumo Interventional Systems (TIS), a strategic business unit
of Terumo Medical Corporation, directly markets a full line of
guidewires, catheters, introducer sheaths, guiding sheaths and
embolization products for use in a multitude of different
interventional procedures. Interventional Radiologists,
Interventional Neuroradiologists, Interventional Cardiologists, and
Vascular Surgeons are among the medical professionals that depend
upon TIS products to access and cross difficult-to-reach lesions,
thereby allowing therapeutic intervention in previously unreachable
vascular beds.
Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo
Medical Corporation (TMC) develops, manufactures, and markets
high-quality medical devices used in a broad range of applications
in numerous healthcare markets. TMC manufactures a broad portfolio
of needles and syringes, entry-site management products, and a line
of sterile connection devices used in hospitals and blood banks
worldwide.
Terumo Corporation
Tokyo-based Terumo Corporation
is one of the world's leading medical device manufacturers with
$4.0 billion in sales and operations
in more than 160 nations. Founded in 1921, the company
develops, manufactures, and distributes world-class medical devices
including products for use in cardiothoracic surgery,
interventional procedures, and transfusion medicine; the company
also manufactures a broad array of syringe and hypodermic needle
products for hospital and physician office use. Terumo
contributes to society by providing valued products and services to
the healthcare market and by responding to the needs of healthcare
providers and the people they serve. Terumo Corporation's
shares are listed on the first section of the Tokyo Stock Exchange
(No. 4543, Reuters symbol , or Bloomberg 4543: JP) and
is a component of the Nikkei 225, Japan's leading stock index.
SOURCE Terumo Americas Holding, Inc.